Literature DB >> 33747358

Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology.

Bryony J Telford1, Sanaz Yahyanejad1, Thijs de Gunst1, Harm C den Boer1, Rogier M Vos1, Marieke Stegink1, Marion T J van den Bosch1, Mir Farshid Alemdehy1, Laurens A H van Pinxteren1, Roel Q J Schaapveld1, Michel Janicot1.   

Abstract

Compelling evidence demonstrates that miR-193a-3p is a tumor suppressor microRNA in many cancer types, and its reduced expression is linked to cancer initiation and progression, metastasis, and therapy resistance. However, its mechanism of action is not consistently described between studies, and often contradicts the pleiotropic role of a microRNA in manipulating several different mRNA targets. We therefore comprehensively investigated miRNA-193a-3p's mode of action in a panel of human cancer cell lines, with a variety of genetic backgrounds, using 1B3, a synthetic microRNA mimic. Interestingly, the exact mechanism through which 1B3 reduced cell proliferation varied between cell lines. 1B3 efficiently reduced target gene expression, leading to reduced cell proliferation/survival, cell cycle arrest, induction of apoptosis, increased cell senescence, DNA damage, and inhibition of migration. SiRNA silencing of 1B3 target mRNAs further highlighted the advantage of the pleiotropic mechanism of 1B3 action, as repression of individual targets did not achieve the same robust effect on cell proliferation in all cell lines. Importantly, a novel lipid nanoparticle-based formulation of 1B3, INT-1B3, demonstrated marked anti-tumor activity as a single agent following systemic administration in tumor-bearing mice. Together, these data strongly support the development of 1B3 as a novel therapeutic agent for treatment of human cancer. Copyright:
© 2021 Telford et al.

Entities:  

Keywords:  miR-193a-3p; microRNA delivery in vivo; microRNA mimic; pleiotropic mechanism of microRNA

Year:  2021        PMID: 33747358      PMCID: PMC7939530          DOI: 10.18632/oncotarget.27894

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  49 in total

Review 1.  MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship.

Authors:  Amy E Pasquinelli
Journal:  Nat Rev Genet       Date:  2012-03-13       Impact factor: 53.242

2.  Demethylation of miR-9-3 and miR-193a genes suppresses proliferation and promotes apoptosis in non-small cell lung cancer cell lines.

Authors:  Jinliang Wang; Bo Yang; Lu Han; Xiaoyan Li; Haitao Tao; Sujie Zhang; Yi Hu
Journal:  Cell Physiol Biochem       Date:  2013-12-13

3.  Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1.

Authors:  Jeong-Eun Kwon; Bu-Yeon Kim; Seo-Young Kwak; In-Hwa Bae; Young-Hoon Han
Journal:  Apoptosis       Date:  2013-07       Impact factor: 4.677

4.  MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.

Authors:  X-N Gao; J Lin; Y-H Li; L Gao; X-R Wang; W Wang; H-Y Kang; G-T Yan; L-L Wang; L Yu
Journal:  Oncogene       Date:  2011-03-14       Impact factor: 9.867

Review 5.  Tumour heterogeneity and the evolutionary trade-offs of cancer.

Authors:  Jean Hausser; Uri Alon
Journal:  Nat Rev Cancer       Date:  2020-02-24       Impact factor: 60.716

6.  MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.

Authors:  T Yu; J Li; M Yan; L Liu; H Lin; F Zhao; L Sun; Y Zhang; Y Cui; F Zhang; J Li; X He; M Yao
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

Review 7.  Development of therapeutic combinations targeting major cancer signaling pathways.

Authors:  Timothy A Yap; Aurelius Omlin; Johann S de Bono
Journal:  J Clin Oncol       Date:  2013-03-18       Impact factor: 44.544

Review 8.  Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Garima Sharma; C George Priya Doss; Sang-Soo Lee
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-12       Impact factor: 8.886

Review 9.  The Potential for microRNA Therapeutics and Clinical Research.

Authors:  Johora Hanna; Gazi S Hossain; Jannet Kocerha
Journal:  Front Genet       Date:  2019-05-16       Impact factor: 4.599

10.  Down-Regulation of MiR-193a-3p Dictates Deterioration of HCC: A Clinical Real-Time qRT-PCR Study.

Authors:  Yongru Liu; Fanghui Ren; Yihuan Luo; Minhua Rong; Gang Chen; Yiwu Dang
Journal:  Med Sci Monit       Date:  2015-08-11
View more
  4 in total

Review 1.  The Role of MiR-181 Family Members in Endothelial Cell Dysfunction and Tumor Angiogenesis.

Authors:  Chun Yang; Victor Passos Gibson; Pierre Hardy
Journal:  Cells       Date:  2022-05-18       Impact factor: 7.666

Review 2.  Therapeutic Metabolic Reprograming Using microRNAs: From Cancer to HIV Infection.

Authors:  Mark S Gibson; Cláudia Noronha-Estima; Margarida Gama-Carvalho
Journal:  Genes (Basel)       Date:  2022-01-29       Impact factor: 4.096

Review 3.  Clinical progress of nanomedicine-based RNA therapies.

Authors:  Siyoung A Lim; Alysia Cox; Madelynn Tung; Eun Ji Chung
Journal:  Bioact Mater       Date:  2021-10-22

4.  Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis.

Authors:  Weinan Guo; Zhenjie Wu; Jianru Chen; Sen Guo; Weiming You; Sijia Wang; Jinyuan Ma; Huina Wang; Xiangxu Wang; Hao Wang; Jingjing Ma; Yuqi Yang; Yangzi Tian; Qiong Shi; Tianwen Gao; Xiuli Yi; Chunying Li
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.